“Our key message is that, while antibiotics are necessary and life-saving treatment for many infants...
Investigators at BC Children’s Hospital are taking a fresh approach to improving outcomes for childr...
The Child & Family Research Institute is committed to the education and training of our research community including full-time trainees (masters and doctoral students, postdoctoral fellows and clinical research trainees), summer students, and clinical research coordinators.
First established in 2003, the Research Education Office at the Child & Family Research Institute organizes education and networking events for trainees, coordinators and the public, including the annual Mini Med School series; administers trainee funding competitions; and manages the institute's summer student research program for undergraduate and medical students.
For more information on the education and training opportunities at CFRI and to access the Research Education Program event calendar visit the CFRI Training website.
Investigator, BC Children's Hospital
Clinical Assistant Professor, Division of Pathology and Laboratory Medicine, Department of Medicine, University of British Columbia
BC Children's Hospital
4500 Oak Street
Vancouver, BC V6H 3N1
For more information about the BioBank initiative you can go to the following website: bcchr.ca/biobank Minimal Residual Disease testing
Minimal Residual Disease (MRD) is the name given to small numbers of malignant cells that remain in the patient during or after treatment when the patient has no signs or symptoms of the disease. It is very important to see whether patients still have MRD as it may mean they need more or different treatments. Flow cytometry methods lookat markers on the cell surface of cells or inside the cell. Malignant cells often have a different expression pattern of markers comapred to normal cells and therefore using this method we can distinguish between normal and malignant cells in a large number of patients with acute lymphoblastic leukemia (ALL).
In our laboratory we routinely test all patients with ALL for MRD at day 8 in their blood and Day 29 in bone marrow by a method called flow cytometry. We are currently investigating new markers to detect MRD more specifically and in more patients with ALL. We are also working on a method to detect MRD in patients with Acute Myeloid Leukemia (AML). In addition, we are doing research in collaboration with Dr. Strahlendorf and Dr. Tanya Brown to see whether we can detect minimal disease as well as MRD in the bone marrow of patients with a solid tumor called neuroblastoma.